APLT:NSD-Applied Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 13.54

Change

-0.72 (-5.05)%

Market Cap

USD 0.35B

Volume

0.13M

Avg Analyst Target

USD 22.50 (+66.17%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Address: 545 Fifth Avenue, New York, NY, United States, 10017

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.72 (-1.56%)

USD173.59B 50.81 42.25
BNTX BioNTech SE

-20.17 (-5.62%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

-10.99 (-1.69%)

USD69.72B 11.77 9.06
VRTX Vertex Pharmaceuticals Incorpo..

-2.63 (-1.40%)

USD48.85B 24.83 16.63
BGNE BeiGene Ltd

-4.64 (-1.15%)

USD42.80B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+2.85 (+1.82%)

USD28.42B 48.74 39.11
GMAB Genmab A/S

-0.18 (-0.42%)

USD28.19B 71.63 8.17
RPRX Royalty Pharma plc

-1.67 (-4.34%)

USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

-6.88 (-3.61%)

USD21.80B N/A N/A

ETFs Containing APLT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.48% 23% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.48% 23% F 12% F
Trailing 12 Months  
Capital Gain -39.62% 22% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.62% 22% F 8% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 29.91% 62% D- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.91% 62% D- 74% C
Risk Return Profile  
Volatility (Standard Deviation) 107.86% 25% F 15% F
Risk Adjusted Return 27.73% 53% F 41% F
Market Capitalization 0.35B 50% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.32 54% F 42% F
Price / Cash Flow Ratio -4.53 33% F 63% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -85.34% 32% F 20% F
Return on Invested Capital -163.41% 8% F 4% F
Return on Assets -45.12% 14% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 12.53 14% F 7% F
Short Percent 7.86% 35% F 22% F
Beta 1.13 62% D- 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.